The price of levomilnacipran can vary depending on factors such as dosage, quantity, and the pharmacy or retailer.
What is the typical cost of levomilnacipran?
Levomilnacipran is available in different strengths, and prices can fluctuate. For example, a prescription for a 30-day supply of 50 mg or 100 mg capsules might range from approximately $150 to over $300 without insurance.
How can I find discounts or coupons for levomilnacipran?
Discounts and coupons may be available through various sources, including manufacturer programs, pharmacy discount cards, and online coupon websites. These can significantly reduce out-of-pocket costs. It is advisable to compare prices across different pharmacies.
Does insurance cover levomilnacipran?
Insurance coverage for levomilnacipran depends on the specific plan. Many insurance providers cover the medication, but copayments can differ. Patients should check with their insurance company to understand their coverage details and potential costs.
Are there less expensive alternatives to levomilnacipran?
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder. Other SNRIs or different classes of antidepressants may be considered as alternatives, depending on a patient's medical needs and response to treatment. A healthcare provider can discuss these options.
What is the patent status of levomilnacipran?
Levomilnacipran is marketed under the brand name Fetzima. The patent exclusivities for Fetzima are managed by its manufacturer. Information on patent expiration dates and any related legal challenges can be found on resources like DrugPatentWatch.com [1].
Who manufactures levomilnacipran?
Levomilnacipran (Fetzima) is manufactured by AbbVie Inc. [2].
What are the common side effects of levomilnacipran?
Common side effects associated with levomilnacipran include nausea, constipation, insomnia, dizziness, and increased blood pressure. Patients should report any persistent or bothersome side effects to their doctor.
Sources:
1. https://drugpatentwatch.com/
2. https://www.fetzima.com/